An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

Clinical trial NCT06487624 · RECRUITING

Trial details

NCT number: NCT06487624
Sponsor: FBD Biologics Limited
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumor Refractory Hodgkin Lymphoma

Start date: 2025-04-02
Primary completion: 2026-12-31
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.